MK-677 (ibutamoren): raises the hormones, not (yet) the outcomes

MK-677 is one of the best-documented compounds in the “growth hormone” corner of the peptide world — which is exactly why it’s a useful case study in the difference between a drug that moves a biomarker and a drug that improves an outcome. MK-677 does the first reliably. The evidence that it does the second is, so far, missing — and there are safety signals worth taking seriously.

What it is

MK-677 (ibutamoren, originally MK-0677) is an orally active ghrelin mimetic — a growth hormone secretagogue. It is not itself a peptide; it’s a non-peptide small molecule that mimics ghrelin to amplify the body’s own pulsatile GH release, which in turn raises IGF-1.^[1][5] Because it’s oral and long-acting, a single daily dose sustains elevated IGF-1 — a different route to the same axis targeted by injectable GHRH analogs like sermorelin and peptides like ipamorelin / CJC-1295.

What the trials reliably show: IGF-1 and lean mass

On its core pharmacology, MK-677 delivers. In healthy elderly subjects, 25 mg once daily raised 24-hour GH by about 97% and lifted IGF-1 into the young-adult range.^[5] In obese men, eight weeks of 25 mg raised IGF-1 roughly 40% and significantly increased fat-free mass.^[6] The landmark trial — a 2-year randomized, placebo-controlled study in healthy older adults — found MK-677 increased fat-free mass by 1.1 kg versus a 0.5 kg loss on placebo, while restoring GH and IGF-1 toward young-adult levels.^[1]

The catch: the biomarkers moved, the outcomes didn’t

Here is the part the muscle-forum enthusiasm skips. In that same 2-year trial, the authors were blunt: the increased fat-free mass “did not result in changes in strength or function.”^[1] And in the two settings where MK-677 was actually tested for a clinical outcome, it failed. In a 563-patient trial it raised IGF-1 by 72.9% but had no effect on Alzheimer’s progression on any cognitive endpoint.^[2] In a hip-fracture rehabilitation trial it raised IGF-1 but did not improve most functional measures — and was terminated early for a heart-failure safety signal.^[3]

The safety signals

Two are worth flagging. First, MK-677 consistently raises fasting blood glucose and reduces insulin sensitivity — seen across the older-adult, elderly, and obese-men trials.^[1][5][6]For anyone with prediabetes or metabolic risk, that is not a minor footnote. Second, the hip-fracture trial’s congestive heart-failure signal led its authors to conclude MK-677 had an “unfavorable safety profile” in that population.^[3] Common, milder effects include increased appetite, transient lower-leg edema (water retention), and muscle pain.^[1]The full picture is in our MK-677 side effectsbreakdown.

Regulatory status

MK-677 was developed by Merck and taken through multiple trials but was never approved or marketed — it remains an investigational compound, and what people buy is sold as a “research chemical,” not a regulated medicine. As a growth hormone secretagogue it is also prohibited in sport. There is no FDA-approved MK-677 product and therefore no official dose; what the trials used is covered in our dosage guide.

The honest bottom line

MK-677 is the rare research compound with a deep, reproducible human evidence base — and that evidence cuts against the hype. It reliably raises GH, IGF-1 and lean mass, but the controlled trials consistently failed to show that those changes translate into strength, function, cognition or recovery, and they surfaced real metabolic and cardiac safety signals.^[1][2][3]Treat it as a proven biomarker-mover with unproven benefits and genuine risks — not a safe shortcut to growth-hormone’s promised effects. For how it compares with the injectable alternative, see MK-677 vs sermorelin.